# Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

> **NCT03276156** · PHASE1 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Apatinib plus S-1

## Key facts

- **NCT ID:** NCT03276156
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02-23
- **Primary completion:** 2018-02-22
- **Final completion:** 2018-02-22
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2017-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276156, "Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03276156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*